• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Authors Posts by admin

admin

2176 POSTS 0 COMMENTS
https://psynews.com

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt...

California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments

PT437 – Exploring Psychedelic Therapies: Iboga, CBD, and Cannabis Paired With...

Natural Medicine Advisory Bulletin #3: August 2023

Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft...

FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA

BREAKING: Big Pharma Company Otsuka to Acquire Mindset Pharma for CAD...

COMPASS Pathways to participate in upcoming September investor conferences

PT436 – The Power of Sound: The Magic in Live Performances,...

Cybin Set to Acquire British DMT Drug Developer Small Pharma

1...484950...218Page 49 of 218

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©